Cura therapeutics is developing innovative immunotherapies to cure a wide range of cancers, specifically solid malignancies.
Our technologies harness cytokines and cytokine receptors to create multi-functional proteins with potent anti-cancer properties. Our proprietary technology FIST a chimeric protein that simultaneously combines a lymphocyte-stimulatory property of IL-2 while blocking the suppressive effects of tumor-derived transforming growth factor beta (TGFb).
Our chimeric proteins can be used alone or in combination with a wide range of other target therapies or cell-based therapies such as immune checkpoint inhibitors or CART therapies.
Cura Therapeutics is actively seeking strategic partnering opportunities, and collaborations with pharmaceutical and biotechnology companies to develop and commercialize cancer immunotherapies based on our multifunctional fusion proteins.